Brett Zbar, MD, is a Managing Director and Global Head of General Atlantic’s Life Sciences sector. Before joining General Atlantic in 2020, Brett was a Managing Director at Foresite Capital, where he focused on backing leading healthcare entrepreneurs and companies at all stages. Prior to that, he was a Partner at Aisling Capital, where he invested in Life Sciences companies developing and commercializing innovative healthcare products, services and technologies.

In his prior investing roles, Brett served as a board member or observer at multiple companies including Aragon (acquired), Catalent (IPO), ConnectiveRx, Kinnate Biopharma (IPO), ORIC Pharmaceuticals (IPO), Peloton Therapeutics (acquired), Pharvaris (IPO), Planet Biopharmaceuticals (acquired), Replimune (IPO), Seragon (acquired), Signant Health, Turning Point Therapeutics (IPO, acquired) and VenatoRx Pharmaceuticals.

Earlier in his career, Brett was a senior member of the Pharmaceuticals and Medical Products practice at McKinsey & Company. He completed his internship in internal medicine on the Osler Medical Service at Johns Hopkins Hospital.